The Drug That Ate Your
Business Model
GLP-1 receptor agonists (GLP-1 RAs) are no longer only a clinical breakthrough, they are a macro-economic force. About one in eight US adults is currently taking one, and nearly one in five has taken one at some point. Industries built on habitual craving are watching their unit economics shift underneath them.
GLP-1 receptor agonists (GLP-1 RAs) are emerging as a significant disruption to consumer behavior, challenging long-standing assumptions that have shaped food and consumer strategies for decades. Twenty-one percent of US households now include a current user, up from 9% in January 2025. Grocery spending in those households falls measurably within six months, and the declines concentrate in the categories built on habitual purchase. The question is no longer if your category is impacted, but whether you are attempting to defend a status quo that has already been reshaped by changes in appetite, food preferences, and reward-related behaviors.
This brief update examines the transition through three lenses: what the drug does to reward and appetite, where the risks sit, and which positions remain unclaimed.
Key Findings
1.
Disruption goes beyond the gut. GLP-1 drugs act on reward-related brain pathways, not just appetite. It reduces cravings for food, with effects extending to alcohol and, more tentatively, nicotine. In a randomized controlled trial, semaglutide drove a 41.1% reduction in heavy drinking days, 13.7% greater than placebo. Because the mechanism is neurochemical rather than behavioral or seasonal, any business model built on habitual repurchase is now potentially vulnerable.
2.
Satiety is solved. Micronutrient density is not. The drug already suppresses appetite. Products offering more fullness are redundant for active GLP-1 medication users. The real opportunity lies in micronutrient integrity, such as calcium, vitamin D, and magnesium, to bridge the potential intake gaps.
3.
The bone loss risk is documented. Significant bone mineral density loss has been observed in users without exercise protocols. These clinical risks are silent, can develop without symptoms, and represent an opportunity to provide a more complete approach.
4.
A 57-point support gap remains unclaimed. 74% of users want mental health support. Only 17% receive it. This misalignment between demand and provision is the primary entry point for a new category of integrated care platforms.
5.
The playbook has been contradicted. Assumptions that muscle loss is minor or that protein shakes alone solve the depletion problem are being contradicted by clinical evidence. Strategic resilience requires a fundamental update to consumer health models.
$64.4B
global GLP-1 market size (2025)
1 in 8
U.S. adults have used GLP-1 RAs (2024)
21%
of US households include a current GLP-1 user, up from 9% in January 2025
-5.3%
average grocery spend decline within six months of starting therapy, and more than 8% among higher-income households
$114B
projected global market opportunity for obesity drugs by 2030
46.5%
of patients with type 2 diabetes and 64.8% without discontinued within twelve months in a 2025 analysis of 125,474 adults.
The death of the default craving
The entire food industry is preparing for a consumer who eats less. That is the wrong consumer to prepare for.
GLP-1 receptor agonists do not simply tell the stomach to feel full. Receptors are present on neurons in the human medulla, hypothalamus, and parietal cortex, and GLP-1 analogues reduce activation in reward-related regions including the insula and putamen in response to desirable food cues. These effects extend beyond food, with emerging evidence suggesting reduced cravings for alcohol and nicotine. Weight loss is driven largely by reduced energy intake, through both appetite and reward-related mechanisms. Companies building strategy around the appetite alone may be missing a broader shift in consumer behavior.
The scale of what is already in market makes this a present-tense problem, not a future-state one:
- The number of U.S. patients without diabetes starting GLP-1 treatment grew 700% between 2019 and 2023.
- Fast food and limited-service restaurant spending fell 8%.
- The largest declines were concentrated in calorie-dense processed categories, including a 10.1% drop in savory snacks.
Every industry built on habitual consumption is already operating inside this disruption. Most are still treating it as a dietary trend.
Gareth Armanious, PhD
Technical Director | PreScouter
The category is mostly planning against one drug and one patient, and both assumptions have a shelf life. Appetite suppressants are a drug class now, and each generation should be easier to use with a milder side effect profile, which makes the nutritional and behavioural support needs of this population a moving target. There are second-order effects to think about: clothing sizes turn over, and hydration and fibre needs rise in a market that has already primed consumers to want fibre. The stable planning variable is phase of treatment. Pre-use, in-treatment and post-discontinuation are three different consumers, and many people cycle between them rather than staying in one.
General grocery
−5.3%spending
Within 6 months of GLP-1 adoption
Savory snacks
−10.1%spending
Within 6 months of GLP-1 adoption
Fast food / dining
−8.0%spending
Within 6 months of GLP-1 adoption
Household Reach
Exposure within the home may be the unit that is more meaningful than individual patient counts. When one member starts treatment, purchasing can shift across the whole household, which makes household penetration a more useful denominator for a category manager than patient count. Circana projects that households using GLP-1 medications will account for 35% of all U.S. food and beverage units sold by 2030.
35%
U.S. F&B unit sales by 2030 (Circana)
Carrie Gabriel, MS, RDN
Registered Dietitian | CulinArt Group
There is more of a tolerance vs. appetite decision when it comes to eating. People will pull back on heavier, greasier, spicier foods if it induces nausea, acid reflux, or general GI discomfort. Impulse snacking subsides, food noise is lowered, and people become more selective, leaning toward protein-forward, simple meals that make them feel their best physically.
Solving a problem the drug already solved
Appetite suppression is the one thing the drug handles without assistance. A study drawing on a sample of 22,691 U.S. households found that households with at least one GLP-1 user reduced grocery spending by 5.3% within six months of starting treatment. These are not consumers struggling to eat less. They are already eating significantly less, and the question that matters is whether what they do eat contains enough nutritional density to prevent physiological decline. Formulating for satiety in this population is solving a problem the prescription already solved.
The food and supplement response has been fast and visible. Nestlé launched Vital Pursuit, a high-protein, portion-controlled meal line. Herbalife introduced a GLP-1 Nutrition Companion built around protein shakes and fibre. The Vitamin Shoppe followed with a dietitian-formulated nutrient powder combining protein with broad vitamin and mineral support.
These are competent products, and the micronutrient logic behind them is sound. When caloric intake drops sharply and stays low, access to micronutrients such as calcium, vitamin D, and magnesium drops with it, and protein alone does not close the gap. That is where the real opportunity sits, not in helping people eat less, but in making sure what they do eat still covers what the body needs.
Expert Commentary
Victoria Yeung, MBS
Senior Project Architect | PreScouter
The products that will matter in three years are being built on the biology of this specific population, not on what worked for diet culture in 2015. In CPG product development, the instinct is always to lead with the benefit the consumer can feel immediately. Satiety is tangible. Bone density is not. The problem is that GLP-1 users are not a standard calorie-restriction cohort. Their nutritional exposure window is compressed in ways that legacy formulation playbooks were never designed to address.
- Research Publication
Get the complete GLP-1 strategic disruption analysis
A deep-dive into how GLP-1 drugs are changing consumer cravings, category demand, and long-term market strategy. The brief examines exposed industries, nutrient gaps, and the platform opportunities emerging around integrated care.
The invisible skeletal deficit
Muscle loss from GLP-1 therapy has entered the mainstream conversation. Fitness brands are responding. Protein is being repositioned. Noom built a Muscle Defense protocol. Equinox launched a GLP-1-specific strength program. The industry has identified lean mass preservation as the primary physiological challenge and organized around it. Muscle mass tells a different story. In a meta-analysis of randomized controlled trials of GLP-1 receptor agonists, lean mass accounted for approximately 25% of total weight loss, a concern that may become more relevant with age. The brands leading the initial product wave appear to be addressing only part of the nutritional challenge. That response is correct and incomplete, because it is addressing the visible risk while another clinically relevant risk may develop undetected.
Bone loss does not show up in the mirror. It does not initially produce noticeable fatigue or weakness that a user can attribute to their medication. It does not appear in any initial consumer-facing metric. It can show up years later as a fracture, a density scan, a diagnosis. A 2024 randomized study tracked bone mineral density at the hip, spine, and forearm across four intervention groups over 52 weeks. The group receiving liraglutide without exercise showed significant BMD reductions at both the hip and lumbar spine by the end of the study. The exercise-plus-liraglutide group showed substantially less loss, pointing directly at the intervention.
Expert Commentary
Thuy Ngo, PhD
Project Architect | PreScouter
Bone health is still getting less attention in the GLP-1 conversation than muscle preservation. I would not say GLP-1 therapy itself causes bone loss; the evidence there is still developing. What we do know is that substantial weight loss, less mechanical loading on the skeleton, and inadequate calcium and vitamin D can all affect bone health. Those are conditions this population may experience. That is the case for designing for muscle and bone together, rather than treating protein as the whole answer.
The nutritional gap that drives bone loss is also more complex than the muscle conversation acknowledges. Protein matters for lean mass, while bone health also depends on adequate calcium, vitamin D, and other nutrients involved in bone metabolism. A GLP-1 user relying on a high-protein shake may still have broader nutritional needs that are relevant to bone health. Existing GLP-1 products already combine protein with broad vitamin and mineral support, but there remains an opportunity to address muscle preservation and bone health together with greater specificity for this population.
The nutritional gap that drives bone health is also more complex than the muscle conversation acknowledges. Protein matters for lean mass, while bone health also depends on adequate calcium, vitamin D, and other nutrients involved in bone metabolism. A GLP-1 user relying on a high-protein shake may still have broader nutritional needs that are relevant to bone health. Existing GLP-1 products already combine protein with broad vitamin and mineral support, although the extent to which these products address the specific needs of this population varies.
Download the GLP-1 Strategic Report
Get the complete analysis, including detailed category risk profiles, potential nutrient gaps data, and the full expert panel commentary.
Rituals without rewards: Alcohol & tobacco
The category-level reading of GLP-1 inside some beverage alcohol strategy decks is that the impact is real but manageable, a modest volume headwind concentrated among health-conscious consumers who were probably drinking less anyway. That conclusion misses what the mechanism may actually be impacting.
The reduction in alcohol consumption among GLP-1 users may extend beyond the downstream effect of eating less, feeling healthier, or making better lifestyle choices. GLP-1 receptors are expressed in brain reward circuitry, and preclinical evidence shows that GLP-1 receptor activation can dampen dopamine signaling associated with reward. Emerging clinical evidence also suggests effects beyond food, including reduced alcohol and nicotine craving.
The tobacco picture appears structurally similar. A 2021 randomized pilot trial found that exenatide raised smoking abstinence rates from 26.8% to 46.3% when combined with standard nicotine patch therapy. The mechanism here may be similar: preclinical data indicate that GLP-1 receptor activation can modulate mesolimbic reward circuitry and reduce nicotine reinforcement.
Expert Commentary
Jorge Hurtado, PhD
Senior Analyst | PreScouter
GLP-1 is a faster and more persistent version of that shift, because the mechanism is not cultural. It is chemical. The historical precedent that matters here is not in pharma. It is in how the alcohol industry responded to the drunk driving campaigns of the 1980s, which created an entirely new non-alcoholic occasion. The brands that moved early built category leadership that held for decades. The ones that waited defended volume until they couldn’t.
The data supports this being more than a dietary shift. In a randomized controlled trial of patients with alcohol use disorder and obesity, semaglutide drove a 41.1% reduction in heavy drinking days, 13.7% greater than placebo. The drug is not helping consumers make better choices. It is changing what they want.
The Dopamine Loop Disruption
Preclinical evidence indicates that GLP-1 receptor activation in reward-related circuits may reduce the reinforcing value of nicotine and alcohol. This indicates it is not a choice-based lifestyle shift; it is potentially a fundamental neurochemical modulation of reward response to stimulus.
The unclaimed strategic platform
The conversation about GLP-1 opportunities has been organized almost entirely around products. Which supplement wins the micronutrient gap. Which beverage brand captures the alcohol occasion. Which fitness platform builds the muscle preservation protocol. Those are real opportunities and they are being pursued. What remains underdeveloped at a meaningful scale is the position that sits above all of them: the integrated support relationship with the GLP-1 user across the full arc of their treatment journey.
- Integrated Platform Single user relationship 01
- Behavioral Health Mood & cravings management 02
- Nutrition Counseling Micronutrient optimization 03
- Pharmacological Monitoring Protocol & adherence 04
Market imbalance
The behavioral support gap
The platform opportunity
57 percentage point strategic void
The behavioral health data makes the gap visible. A 2024 survey of 300 GLP-1 users conducted by MARC Research in partnership with Evernorth found that 74% were interested in mental health support, while only 17% used behavioral health or talk therapy. Sixty-three percent believed they would achieve better health with mental health support while taking GLP-1s.
The transition crisis
Among former users who had stopped treatment, 48% reported worsened mental health in the prior year, compared to 29% of current users.
48%
Worsened mental health post-drug
These numbers do not describe a population with a side effect problem. They describe a population undergoing a significant behavioral change, with a clear demand for support that the current care infrastructure is not meeting. The drug is doing something real to how these people experience reward, motivation, and craving. The care model has not caught up.
The Wisp-Nourish partnership is an early signal of what the integrated model looks like in practice. Wisp, a women’s health telehealth provider, partnered with Nourish to offer nutrition counseling to GLP-1 patients as part of their weight management program, accessible through insurance or discounted self-pay. It addresses nutrient intake, supports behavioral change through personalized guidance, and extends the care relationship beyond the prescription.
It is not comprehensive, and it is a desirable shape. A platform combining telehealth, nutrition counselling, resistance training programming, behavioural health, and monitoring across all three phases, from pre-GLP-1 Receptor Agonists use through treatment and post-discontinuation, would own a relationship no single SKU can compete with.
Expert Commentary
Victoria Yeung, MBS
Senior Project Architect | PreScouter
The brands that see it as a product adjacency will build supplements. The brands that see it as a platform opportunity will build something that compounds. What the data tells you is that GLP-1 users are not passive. They are actively seeking support that the current market is not providing. Seventy-four percent raising their hand for behavioral help is a category waiting to be built.
Strategic questions
01
Are you solving for the mechanism or the symptom?
In GLP-1, companies building only for appetite suppression are solving for part of the mechanism. The broader disruption also involves reward pathways, with effects extending beyond food into alcohol and, more tentatively, nicotine. Every large disruption has an equivalent distinction between what is visibly happening and what is actually driving it. The strategy built on the visible thing will be outpaced by the one built on the mechanism.
02
What does your portfolio look like if the craving disappears?
GLP-1 does not reduce consumption by making people more disciplined. It can also reduce reward and craving signals that help reinforce repeated behavior. Any business that depends on habitual repurchase should stress-test its model against a consumer who no longer experiences the craving that drove the habit. If the value proposition only works when the want is intact, the brand is more exposed than the revenue line currently suggests.
03
Are you moving on the invisible risk or waiting for the visible one?
Bone loss is not readily visible in consumer complaints or product returns. It is showing up in clinical data that most product teams have not read. The visible risk in GLP-1 is lean mass loss, and the market is already responding. The invisible risk is bone density decline, and the market is not. In every disruption, the invisible risk is where the first-mover advantage is largest and the window is longest, because most competitors are still watching the visible one.
04
Is the gap between what your customer needs and what you offer a problem or a position?
Seventy-four percent of GLP-1 users want behavioral support. Seventeen percent are receiving it. That 57-point gap is not a failure of awareness. It is a market that has not yet been built. In any disruption, the largest unmet need is not always obvious to the incumbents closest to it. The question is whether you see the gap as someone else’s problem to solve or as the highest-value position available to you.
05
Does your response timeline survive the actual pace of adoption?
The number of U.S. patients without diabetes starting GLP-1 treatment grew 700% between 2019 and 2023. Oral formulations are positioned to lower a key adoption barrier by removing the injection, and a pipeline of next-generation appetite suppressants sits behind them. This points to a drug class that becomes easier to use and better tolerated over time rather than one that fades. The planning horizon most companies are using is not calibrated to that curve.
06
Does GLP-1 adoption make the fibre trend durable?
Fibre is currently riding a consumer trend, and trends cycle out. GLP-1 does not create a new need for fibre, it enlarges an existing one, with constipation common during dose escalation and a user base that keeps growing. A trend with a physiological driver behind it outlasts the point where the trend itself goes quiet. The need is not confined to GLP-1 users either, since most North Americans already fall well short of recommended fibre intake. The decision for a formulator is whether fibre is a front-of-pack claim or a structural requirement in the base formulation, and which fibres are used, since viscosity, fermentation rate, and chain length determine whether a given fibre delivers laxation, glycaemic control, or microbiome benefit, and how well it is tolerated in a population already managing GI side effects.
07
Which phase of the GLP-1 journey are you built for?
A consumer preparing to start, one in month three of dose escalation, and one managing returning appetite after stopping have different needs. Most users cycle rather than stay. Over half stop within a year, and a large share of those restart, usually once weight comes back. The same consumer passes through all three phases, often more than once. Building for the in-treatment user alone leaves the other two to whoever gets there first.
Contributing Experts
Gareth Armanious, PhD
Technical Director | PreScouter
Gareth is the Technical Director of Food & Beverage at PreScouter, where he’s driven strategy and scientific research for Fortune 500s since 2015. He built and leads the F&B team, architecting systems and services that shaped company-wide execution. His expertise spans food, beverage, and life sciences, rooted in a research background in membrane protein biochemistry and prior coordination roles in oncology research.
Victoria Yeung, MBS
Senior Project Architect | PreScouter
Victoria is one of PreScouter’s Project Architects specializing in the Food & Beverage industry. She holds a BS and MBS in Food Science from Rutgers University, where her research focused on identification of photosensitizers for the inactivation of foodborne pathogens. Prior to joining PreScouter, Victoria worked as a scientist at a Fortune 500 consumer packaged goods company, specializing in flavor technology and driving innovations across R&D.
Thuy Ngo, PhD
Project Architect | PreScouter
Thuy earned her PhD degree in Advanced Fusion Technology from Konkuk University, and her Advanced Master in Intellectual Property Law and Knowledge Management from Maastricht University. Before joining PreScouter, she worked as a Research Professor in the field of Structural Biology at Konkuk University where she researched antibacterial drugs and industrial enzymes by leveraging protein tertiary structure. At PreScouter, she specializes in and manages service delivery for clients in the Food&Bev and Life Sciences sectors. She is currently based in Ho Chi Minh City, Vietnam.
Jorge Hurtado, PhD
Senior Analyst | PreScouter
Jorge works as a Senior Analyst at PreScouter. His expertise spans a broad spectrum of technological fields. He holds a Master’s degree in Conservation and Development, a Ph.D. in Biology from the University of Florida and Syracuse University, respectively, and a diploma in Green Economy from Toronto Metropolitan University.
Carrie Gabriel, MS, RDN
Registered Dietitian | CulinArt Group
Carrie is a registered dietitian with over 13 years of experience, known for blending evidence-based nutrition with practical, culinary-focused guidance. Her work spans recipe development and brand collaborations, as well as nutrition counseling, particularly with women navigating perimenopause, menopause, and GLP-1–related weight management. Carrie specializes in helping people build confidence in home cooking and using whole foods in realistic ways that account for time, budget, and convenience constraints.
References
KFF · Journal of Marketing Research · ScienceDirect · Cambridge University Press · PwC · Journal of Marketing Research · NIH · JCI Insight
JAMA Psychiatry · Europe PMC · PubMed · Evernorth · PubMed Central · Research and Markets · KFF · PwC
Journal of Marketing Research · Goldman Sachs · PubMed Central · PubMed · The BMJ · Journal of Marketing Research · Journal of Marketing Research · Journal of Marketing Research
Circana · Journal of Marketing Research · Nestlé USA · Herbalife · The Vitamin Shoppe · PubMed Central · Noom · Equinox
ScienceDirect · JAMA Network Open · PubMed · PubMed · The Vitamin Shoppe · PubMed · JAMA Psychiatry · JAMA Network Open
PubMed Central · PubMed Central · NIH · PubMed Central · PubMed · Evernorth · JCI Insight · MedCity News